Exact SciencesEXAS
EXAS
About: Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Employees: 7,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
17% more call options, than puts
Call options by funds: $83.1M | Put options by funds: $71.4M
0.98% less ownership
Funds ownership: 98.74% [Q4 2024] → 97.76% (-0.98%) [Q1 2025]
9% less repeat investments, than reductions
Existing positions increased: 173 | Existing positions reduced: 190
6% less funds holding
Funds holding: 581 [Q4 2024] → 544 (-37) [Q1 2025]
23% less capital invested
Capital invested by funds: $10.3B [Q4 2024] → $7.86B (-$2.41B) [Q1 2025]
26% less first-time investments, than exits
New positions opened: 73 | Existing positions closed: 98
43% less funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 4 (-3) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$54
1%
upside
Avg. target
$65
21%
upside
High target
$75
40%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
Barclays Luke Sergott | 40%upside $75 | Overweight Maintained | 2 May 2025 |
RBC Capital Gerard Cassidy | 1%upside $54 | Sector Perform Maintained | 2 May 2025 |
Evercore ISI Group Vijay Kumar | 23%upside $66 | Outperform Maintained | 2 May 2025 |
Baird Catherine Schulte | 35%upside $72 | Outperform Maintained | 2 May 2025 |
Guggenheim Subbu Nambi | 12%upside $60 | Buy Reiterated | 11 Apr 2025 |
Financial journalist opinion
Based on 4 articles about EXAS published over the past 30 days
Neutral
Zacks Investment Research
1 week ago
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
Neutral
Business Wire
2 weeks ago
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinical validation study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Results from Beta-CORRECT, a subset of the GALAXY cohort, validate the performance of its tumor-informed molecular residual disease (MRD) test, Oncodetect™, in predicting recurrence in stage II–IV colorectal.
Neutral
Business Wire
2 weeks ago
Exact Sciences to Participate in June Investor Conference
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. William Blair 45th Annual Growth Stock Conference, Chicago Presentation on Tuesday, June 3, 2025 at 9:40 a.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About E.
Neutral
Business Wire
3 weeks ago
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score® test, and the Cologuard®.
Positive
The Motley Fool
1 month ago
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years
While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more.
Neutral
Business Wire
1 month ago
Exact Sciences Earns 2025 Great Place To Work® Certification™
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany. The recognition is based on a confidential survey of employees around the world, offering an independent assessment of Exact Sciences' culture, work environment, and le.
Positive
Seeking Alpha
1 month ago
Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling
Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue decline, the market response was positive due to promising growth projections and the launch of Cologuard Plus, a next-gen colon cancer screening test. Competition and high market cap valuation pose challenges, but Exact's first-mover advantage and new product launches offer potential for continued revenue growth.
Positive
Benzinga
1 month ago
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance
Exact Sciences Corp. EXAS on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst consensus loss estimate of 38 cents.
Positive
Zacks Investment Research
1 month ago
EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised
Exact Sciences ends the first quarter of 2025 on a solid note.
Neutral
Business Wire
1 month ago
Exact Sciences to Participate in May Investor Conference
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.co.
Charts implemented using Lightweight Charts™